Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $11.2750 (-4.21%) ($11.2400 - $11.7350) on Mon. Jan. 9, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.77% (three month average) | RSI | 34 | Latest Price | $11.2750(-4.21%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.5% a day on average for past five trading days. | Weekly Trend | FOLD declines -0.7% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) XBI(59%) IBB(52%) IWM(42%) IWO(42%) IWC(41%) | Factors Impacting FOLD price | FOLD will decline at least -1.385% in a week (0% probabilities). TBT(-20%) UUP(-12%) VIXM(-9%) VXX(-4%) EDOC(-3%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.385% (StdDev 2.77%) | Hourly BBV | -2.1 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $7.36(-34.72%) | Resistance Level | $11.91 | 5 Day Moving Average | $11.77(-4.21%) | 10 Day Moving Average | $11.8(-4.45%) | 20 Day Moving Average | $11.91(-5.33%) | To recent high | -11.3% | To recent low | 12.8% | Market Cap | $2.911b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |